Results 81 to 90 of about 1,428 (167)
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu +3 more
wiley +1 more source
, 2023 BackgroundThe changes in the estimated glomerular filtration rate (eGFR) and predictors of the renal prognosis were retrospectively assessed over the 12 months after the initiation of tofogliflozin, which has the shortest half-life among sodium-glucose ...
Takuma Izutsu (10305465) +7 more
core +1 more source
British Journal of Pharmacology, Volume 183, Issue 9, Page 1814-1823, May 2026.Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete +2 more
wiley +1 more source
Flowchart of patient selection.
, 2023 The safety of tofogliflozin was analyzed in the safety analysis set (n = 158), and the effectiveness was investigated in the full analysis set (n = 130).
Takuma Izutsu (10305465) +7 more
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami +16 more
wiley +1 more source
, 2022 ObjectiveTo evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).DesignA network meta-analysis.
Yuning Liu (4350469) +5 more
core +1 more source
Weight and food intake of mice fed normal chow or a high-fat diet with/without tofogliflozin.
, 2019 Mice were fed an HFD for 26 weeks from 4 weeks of age. At 30 weeks of age, half of the mice were switched to normal chow (NC) with or without 0.005% tofogliflozin (NC and NC + tofo, respectively) for 38 weeks. The remaining HFD mice received the HFD with
Kohsuke Shirakawa (4233655) +5 more
core +1 more source
非アルコール性脂肪性肝疾患モデルメダカの心筋病変に対する選択的PPARαモジュレーター、ナトリウム-グルコース共輸送体2阻害剤、スタチンの有効性の検討 [PDF]
, 2023 新潟大学Niigata University博士（医学）Objective: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysregulation and is linked with various cardiovascular complications, which often lead to poor prognostic outcomes.
大越, 麻理奈 +1 more
core +1 more source
Journal of Pharmacological Sciences, 2016 The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion.
Atsuo Tahara +4 more
doaj +1 more source
Journal of Pharmacological Sciences, 2016 Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and diabetic mice.
Atsuo Tahara +4 more
doaj +1 more source